New Treatment Guidelines for Sjögren's Disease

Rheumatic Disease Clinics of North America

Volumn 42, Issue 3, 2016, Pages 531-551

  Vivino, Frederick B ^a   Carsons, Steven E ^b,c   Foulks, Gary ^d   Daniels, Troy E ^e   Parke, Ann ^f   Brennan, Michael T ^g   Forstot, S Lance ^h   Scofield, R Hal ⁱ   Hammitt, Katherine M ^j  

^a PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

^c STONY BROOK UNIVERSITY   (United States)

^d University of Louisville School of Medicine   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

^g CAROLINAS MEDICAL CENTER   (United States)

^h Corneal Consultants of Colorado ^*  (United States)

ⁱ UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^j Sjögren's Syndrome Clinic   (United States)

more..

Author keywords

Arthritis; Biologics; Caries; DMARDS; Dry eye; Fatigue; Sj gren's; Treatment

Indexed keywords

ANTIINFECTIVE AGENT; ARTIFICIAL TEAR; AZATHIOPRINE; AZITHROMYCIN; CORTICOSTEROID; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXYCYCLINE; FLUORIDE; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; OMEGA 3 FATTY ACID; PLACEBO; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; ANTICARIES AGENT; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT;

ANGINA PECTORIS; BACTERIAL INFECTION; BIOLOGICAL THERAPY; CRYOGLOBULINEMIA; CYTOPENIA; DENTAL CARIES; DRY EYE; FATIGUE; HEALTH CARE COST; HEART ARRHYTHMIA; HEPATITIS B; HUMAN; INFECTION; INFUSION RELATED REACTION; INTESTINE OBSTRUCTION; INTESTINE PERFORATION; KERATOCONJUNCTIVITIS SICCA; LUNG DISEASE; MEIBOMIAN GLAND DYSFUNCTION; MONONEUROPATHY; MUSCULOSKELETAL PAIN; MYCOSIS; NONHODGKIN LYMPHOMA; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PUNCTAL PLUG; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SCHIRMER TEST; SJOEGREN SYNDROME; TEAR OSMOLARITY; TUMOR LYSIS SYNDROME; VASCULITIS; VIRUS INFECTION; XEROSTOMIA; COST OF ILLNESS; DELPHI STUDY; KINESIOTHERAPY; SELF CARE; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME;

ANTIRHEUMATIC AGENTS; BIOLOGICAL PRODUCTS; CARIOSTATIC AGENTS; COST OF ILLNESS; DELPHI TECHNIQUE; DENTAL CARIES; EXERCISE THERAPY; FATIGUE; FLUORIDES; HEALTH CARE COSTS; HUMANS; HYDROXYCHLOROQUINE; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; RITUXIMAB; SELF CARE; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME;

EID: 84990924498     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2016.03.010     Document Type: Review

References (47)

1. 1 Valtýsdóttir, S.T., Gudbjörnsson, B., Lindqvist, U., et al. Anxiety and depression in patients with primary Sjögren's syndrome. J Rheumatol 27:1 (2000), 165–169.
2. 2 Vitali, C., Tavoni, A., Neri, R., et al. Fibromyalgia Features in Patients with Primary Sjögren's Syndrome: Evidence of a Relationship with Psychological Depression. Scand J Rheumatol 18:1 (1989), 21–27.
3. 3 Mishra, R., Vivino, F.B., Diagnosis and management of fatigue. Wallace, D.J., (eds.) The Sjögren's book, 2012, The Sjögren's Syndrome Foundation and Oxford University Press, New York, 228–234.
4. 4 Segal, B., Bowman, S.J., Fox, P.C., et al. Primary Sjögren's Syndrome: health experiences and predictors of health quality among patients in the United States. Health Qual Life Outcomes, 7, 2009, 46.
5. 5 Strömbeck, B., Ekdahl, C., Manthorpe, R., et al. Health-related quality of life in primary Sjögren's syndrome, rheumatoid arthritis and fibromyalgia compared to normal population data using SF-36. Scand J Rheumatol 29:1 (2000), 20–281.
6. 6 Sutcliffe, N., Stoll, T., Pyke, S., et al. Functional disability and end organ damage in patients with systemic lupus erythematosus (SLE), SLE and Sjögren's syndrome (SS) and primary SS. J Rheumatol 25:1 (1998), 63–68.
7. 7 Bowman, S.J., St Pierre, Y., Sutcliffe, N., et al. Estimating indirect costs in primary Sjögren's syndrome. J Rheumatol 37:5 (2010), 1010–1015.
8. 8 Callaghan, R., Prabu, A., Allan, R.B., et al., UK Sjögren's Interest Group, Direct healthcare costs and predictors of costs in patients with primary Sjögren's syndrome. Rheumatology (Oxford) 46:1 (2007), 105–111.
9. 9 Fox, P.C., Bowman, S.J., Segal, B., et al. Oral involvement in primary Sjögren's syndrome. J Am Dent Assoc 139:12 (2008), 1592–1601.
10. 10 AGREE Collaboration. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. Qual Saf Health Care 12:1 (2003), 18–23.
11. 11 AGREE Research Trust. Appraisal of guidelines for research and evaluation II. 2013. Available at: http://www.agreetrust.org/wp-content/uploads/2013/10/AGREE-II-Users-Manual-and-23-item-Instrument_2009_UPDATE_2013.pdf.
12. 12 Richardson, W.S., Wilson, M.C., Nishikawa, J., et al. The well-built clinical question: a key to evidence-based decisions. ACP J Club 123 (1995), A12–A13.
13. 13 Guyatt, G.H., Oxman, A.D., Vist, G., et al., for the GRADE Working Group. Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:7650 (2008), 924–966.
14. 14 Preferred practice guidelines: dry eye, 2012, American Academy of Ophthalmology Available at: http://one.aao.org/summary-benchmark-detail/summary-benchmarks-complete-set-october-2012 Accessed August 19, 2014.
15. 15 Christensen, L.B., Petersen, P.E., Thorn, J.J., et al. Dental caries and dental health behavior of patients with primary Sjögren syndrome. Acta Odontol Scand 59:3 (2001), 116–120.
16. 16 Zero, D.T., Brennan, M.T., Daniels, T.E., et al. Clinical practice guidelines for oral management of Sjögren disease: Dental caries prevention. J Am Dent Assoc 147:4 (2016), 295–305.
17. 17 Quality of life impact of Sjögren's syndrome. The Moisture Seekers 24 (2006), 1–3.
18. 18 Sjögren's syndrome foundation breakthrough goal survey, 2012, Polaris Marketing Research, Inc.
19. 19 Mertzanis, P., Abetz, L., Rajagopalan, K., et al. The relative burden of dry eye in patients’ lives: comparisons to a U.S. normative sample. Invest Ophthalmol Vis Sci 46 (2005), 46–50.
20. 20 Schiffman, R.M., Walt, J.G., Jacobsen, G., et al. Utility assessment among patients with dry eye disease. Ophthalmology 110 (2003), 1412–1419.
21. 21 The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007). Ocul Surf 5 (2007), 75–92.
22. 22 Sullivan, B.D., Crews, L.A., Messmer, E.M., et al. Correlations between commonly used objective signs and symptoms for the diagnosis of dry eye disease: clinical implications. Acta Ophthalmol 92 (2014), 161–166.
23. 23 Foulks, G.N., Forstot, S.L., Donshik, P.C., et al. Clinical Guidelines for Management of Dry Eye Associated with Sjögren Disease. Ocul Surf 13:2 (2015), 118–132.
24. 24 Smedby, K.E., Vajdic, C.M., Falster, M., et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 111:8 (2008), 4029–4038.
25. 25 Carsons SE, Parke A, Vivino FB, et al. Treatment guidelines for rheumatologic and systemic manifestations of Sjögren's: Use of biologics, management of fatigue and inflammatory musculoskeletal pain. Arthritis Care Res, in press.
26. 26 Gottenberg, J.E., Ravaud, P., Puéchal, X., et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA 312:3 (2014), 249–258.
27. 27 Fox, R.I., Chan, E., Benton, L., et al. Treatment of primary Sjögren's syndrome with hydroxychloroquine. Am J Med 85:4A (1988), 62–67.
28. 28 Fox, R.I., Dixon, R., Guarrassi, V., et al. Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open label study. Lupus 5:Suppl 1 (1996), S31–S36.
29. 29 Tishler, M., Yaron, I., Shirazi, I., et al. Hydroxychloroquine treatment for primary Sjögren's syndrome: its effect on salivary and serum inflammatory markers. Ann Rheum Dis 58:4 (1999), 253–256.
30. 30 Fauchais, A.L., Ouattara, B., Gondran, G., et al. Articular manifestations in primary Sjögren's syndrome: clinical significance and prognosis of 188 patients. Rheumatology (Oxford) 49:6 (2010), 1164–1172.
31. 31 Skopouli, F.N., Jagiello, P., Tsifetaki, N., et al. Methotrexate in primary Sjögren's syndrome. Clin Exp Rheumatol, 14(5), 1996, 555.
32. 32 van Woerkom, J.M., Kruize, A.A., Geenen, R., et al. Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study. Ann Rheum Dis 66:8 (2007), 1026–1032.
33. 33 Khan, O., Carsons, S., Occurrence of rheumatoid arthritis requiring oral and/or biological disease-modifying antirheumatic drug therapy following a diagnosis of primary Sjögren syndrome. J Clin Rheumatol 18:7 (2012), 356–358.
34. 34 Segal, B., Fatigue in primary Sjögren's syndrome. Ramos-Casals, M., (eds.) Sjögren's syndrome: diagnosis and therapeutics, 2012, Springer Verlag, London, 129–143.
35. 35 Strombeck, B.E., Theander, E., Jacobsson, L.T., Effectiveness of exercise on aerobic capacity and fatigue in women with Primary Sjögren's syndrome. Rheumatology (Oxford) 46:5 (2007), 868–871.
36. 36 Virkki, L.M., Porola, P., Forsblad-d'Elia, H., et al. Dehydroepiandrosterone (DHEA) substitution treatment for severe fatigue in DHEA-deficient patients with primary Sjögren's syndrome. Arthritis Care Res (Hoboken) 62:1 (2010), 118–124.
37. 37 Hartkamp, A., Geenen, R., Godaert, G.L., et al. Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjögren syndrome: a randomised controlled trial. Ann Rheum Dis 67:1 (2008), 91–97.
38. 38 Sankar, V., Brennan, M.T., Kok, M.R., et al. Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 50:7 (2004), 2240–2538.
39. 39 Mariette, X., Ravaud, P., Steinfeld, S., et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum 50:4 (2004), 1270–1276.
40. 40 Devauchelle-Pensec, V., Mariette, X., Jousse-Joulin, S., et al. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med 160:4 (2014), 233–242.
41. 41 Faustman, D.L., Vivino, F.B., Carsons, S.E., Treatment of primary Sjögren's syndrome with rituximab: Comment on Devauchelle et al 2014. Ann Intern Med 161:5 (2014), 376–377.
42. 42 Meijer, J.M., Meiners, P.M., Vissink, A., et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62:4 (2010), 960–968.
43. 43 Carubbi, F., Cipriani, P., Marrelli, A., et al. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther, 15(5), 2013, R172.
44. 44 Pijpe, J., van Imhoff, G.W., Vissink, A., et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum 52:9 (2005), 2740–2750.
45. 45 Seror, R., Sordet, C., Guillevin, L., et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome. Ann Rheum Dis 66:3 (2007), 351–357.
46. 46 Gorson, K.C., Natarajan, N., Ropper, A.H., et al. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve 35:1 (2007), 66–69.
47. 47 Gottenberg, J.E., Guillevin, L., Lambotte, O., et al. Club Rheumatismes et Inflammation (CRI). Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64:6 (2005), 913–920.